Anti-PTK7 Antibody Variants for Stable, Longer-Lasting ADCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for more suitable antibody-drug conjugates targeting PTK7 that can achieve efficient, simple, and practical chemical preparation and conjugation, while improving stability, half-life, antitumor drug-resistance properties, and therapeutic window of existing ADC molecules.
Innovation Solution
Development of antibodies or antigen-binding fragments that specifically bind to PTK7, with defined heavy and light chain variable region complementary determining regions (CDRs) sequences, allowing for the creation of antibody-drug conjugates with enhanced stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ADC molecules are used for PTK7 targeting, then antitumor activity is achieved, but stability and half-life are insufficient
Solution Approach 1:
The patent applies parameter changes by developing novel antibody variants with modified amino acid sequences in the CDR regions, specifically optimizing the binding affinity and stability parameters. The antibody variants are engineered to have improved thermodynamic stability and extended serum half-life through systematic parameter optimization of the antigen-binding regions.
Solution Approach 2:
The patent creates composite structures by combining the anti-PTK7 antibody variable regions with optimized constant regions and linker-drug components to form enhanced ADC molecules. The composite design integrates multiple functional elements including the antigen-binding fragment, stabilizing mutations, and cytotoxic payload to achieve improved overall performance.
2Reliability
If existing ADC molecules are used for PTK7 targeting, then antitumor activity is achieved, but therapeutic window is limited
Solution Approach 1:
The patent applies local quality by introducing site-specific mutations in the CDR regions of the antibody to enhance binding specificity to PTK7-expressing tumor cells while maintaining selectivity. The localized optimization of antigen-binding regions improves the therapeutic index by increasing on-target activity without proportionally increasing off-target toxicity.
3Productivity
If complex conjugation methods are used for ADC preparation, then conjugation efficiency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-engineering the antibody variants with optimized cysteine or lysine residues at specific positions that facilitate controlled conjugation. The antibody is prepared in advance with predetermined conjugation sites, enabling simplified and more efficient drug attachment processes while maintaining manufacturing scalability.
Data Source
AI summary
The present disclosure relates to anti-PTK7 antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the same, and use thereof in preparation of antibody-drug conjugates, and further relates to antibody-drug conjugates containing the antibodies or antigen-binding fragments thereof and preparation method and use thereof.